Table 3.
Clinical, functional, disease activity and serological parameters of naïve (n=227) and biological agents failure (n=381) in patients with PsA during 24 months follow up
| T0 | T6 | T12 | T24 | |
| TJ (0–68), mean (SD) | ||||
| Group A | 8.20 (6.71) | 3.47 (4.90) | 2.11 (3.47) | 0.54 (1.02) |
| Group B | 7.91 (6.88) | 3.75 (5.18) | 3.27 (5.38) | 2.11 (3.57) |
| P value | ns | ns | ns | 0.03 |
| SJ (0–66), mean (SD) | ||||
| Group A | 2.19 (2.87) | 0.58 (1.25) | 0.51 (1.97) | 0.15 (0.43) |
| Group B | 2.28 (2.79) | 0.97 (1.67) | 0.66 (1.80) | 0.32 (0.79) |
| P value | ns | ns | ns | ns |
| LEI (0–6), mean (SD) | ||||
| Group A | 1.91 (1.92) | 0.94 (1.37) | 0.30 (0.69) | 0.13 (0.40) |
| Group B | 1.44 (1.76) | 0.83 (1.51) | 0.43 (1.08) | 0.21 (0.70) |
| P value | ns | ns | ns | ns |
| Dactylitis (0–20) number digit, mean (SD) | ||||
| Group A | 0.22 (0.83) | 0.07 (0.62) | 0.03 (0.29) | 0.02 (0.17) |
| Group B | 0.31 (1.48) | 0.08 (0.32) | 0.04 (0.26) | 0.02 (0.13) |
| P value | ns | ns | ns | ns |
| PASI (0–72), mean (SD) | ||||
| Group A | 4.06 (7.09) | 1.63 (3.55) | 0.61 (1.63) | 0.23 (0.55) |
| Group B | 4.34 (7.54) | 1.73 (4.15) | 0.94 (2.49) | 1.14 (3.76) |
| P value | ns | ns | ns | 0.04 |
| ESR (0–25) (mm/hour), mean (SD) | ||||
| Group A | 21.24 (19.32) | 14.23 (11.88) | 13.86 (12.54) | 11.98 (10.44) |
| Group B | 21.24 (19.32) | 16.62 (13.74) | 15.42 (14.11) | 16.10 (13.02) |
| P value | ns | ns | 0.05 | 0.03 |
| CRP (0–6) (mg/L), mean (SD) | ||||
| Group A | 6.01 (9.14) | 3.13 (3.88) | 2.66 (3.50) | 2.12 (3.06) |
| Group B | 6.01 (9.14) | 4.72 (3.77) | 3.84 (5.57) | 4.04 (6.03) |
| P value | ns | ns | ns | 0.05 |
| DAPSA (0–164), mean (SD) | ||||
| Group A | 25.24 (10.91) | 12.06 (8.49) | 10.29 (9.22) | 8.15 (7.95) |
| Group B | 25.36 (11.31) | 15.34 (10.18) | 12.99 (10.21) | 9.42 (8.21) |
| P value | ns | 0.05 | ns | ns |
| ASDAS (0–6), mean (SD) | ||||
| Group A | 3.50 (0.59) | 2.08 (0.93) | 1.88 (0.91) | 1.34 (0.42) |
| Group B | 3.12 (0.99) | 2.12 (1.09) | 1.80 (1.07) | 1.72 (0.76) |
| P value | ns | ns | ns | ns |
| HAQ-S (0–8), mean (SD) | ||||
| Group A | 1.11 (0.74) | 0.69 (0.56) | 0.47 (0.55) | 0.24 (0.35) |
| Group B | 1.39 (0.87) | 1.03 (0.73) | 0.83 (0.75) | 0.65 (0.70) |
| P value | ns | 0.05 | ns | ns |
| VAS-pain (0–10), mean (SD) | ||||
| Group A | 6.62 (1.73) | 4.07 (2.30) | 2.78 (2.46) | 1.62 (1.72) |
| Group B | 6.76 (1.65) | 4.43 (2.26) | 3.56 (2.50) | 3.00 (2.45) |
| P value | ns | ns | 0.05 | 0.04 |
| VAS-gh (0–10), mean (SD) | ||||
| Group A | 5.89 (1.64) | 3.95 (2.24) | 2.43 (2.27) | 1.34 (1.66) |
| Group B | 7.01 (6.08) | 4.43 (2.21) | 3.52 (2.46) | 3.01 (2.40) |
| P value | ns | ns | 0.05 | 0.03 |
| BASDAI (0–10), mean (SD) | ||||
| Group A | 5.23 (2.08) | 3.34 (1.95) | 3.06 (1.96) | 2.14 (1.39) |
| Group B | 5.21 (2.22) | 3.62 (2.82) | 3.51 (2.25) | 2.77 (1.66) |
| P value | ns | ns | ns | ns |
| BASFI (0–10), mean (SD) | ||||
| Group A | 5.02 (2.18) | 3.51 (1.94) | 2.54 (1.59) | 2.01 (0.81) |
| Group B | 5.26 (2.12) | 3.85 (2.07) | 2.99 (1.99) | 2.66 (1.45) |
| P value | ns | ns | ns | ns |
Data are expressed as mean (SD). P≤0.05. Values were computed by means of a χ2 test (for proportion) or Wilcoxon’s test (for continuous data).
The italics character was used to mark the p value.
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C reactive protein; DAPSA, Disease Activity Index for Psoriatic Arthritis; ESR, erythrocyte sedimentation rate; Group A, naïve to TNF inhibitors; Group B, TNF inhibitors and IL-12/23 inhibitors failure; HAQ, Health Assessment Questionnaire modified for spondyloarthritis; LEI, Leeds Enthesitis Index; ns, not statistically significant; PASI, Psoriasis Area Severity Index; SJ, swollen joint; TJ, tender joint; TNF, tumour necrosis factor; VAS-gh, Visual Analogue Scale global health; VAS-pain, Visual Analogue Scale pain.